Federal Register / Vol. 73, No. 22 / Friday, February 1, 2008 / Notices 6187 

industry representative. A current 

curriculum vitae and the name of the 

committee of interest should be sent to 

the FDA contact person (see FOR

FURTHER INFORMATION CONTACT) within 

30 days (see DATES). FDA will forward 

all nominations to the organizations 

expressing interest in participating in 

the selection process for the committee 

(persons who nominate themselves as 

nonvoting industry representatives will 

not participate in the selection process). 

FDA has a special interest in ensuring 

that women, minority groups, 

individuals with physical disabilities, 

and small businesses are adequately 

represented on its advisory committees, 

and therefore, encourages nominations 

for appropriately qualified candidates 

from these groups. 

This notice is issued under the 

Federal Advisory Committee Act (5 

U.S.C. app. 2) and 21 CFR part 14, 

relating to advisory committees. 

Dated: January 24, 2008. 

Randall W. Lutter, 

Deputy Commissioner for Policy. 

[FR Doc. E8–1815 Filed 1–31–08; 8:45 am] 

BILLING CODE 4160–01–S 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Food and Drug Administration 

Vaccines and Related Biological 

Products Advisory Committee; Notice 

of Meeting 

AGENCY: Food and Drug Administration, 

HHS. 

ACTION: Notice. 

This notice announces a forthcoming 

meeting of a public advisory committee 

of the Food and Drug Administration 

(FDA). The meeting will be open to the 

public. 

Name of Committee: Vaccines and 

Related Biological Products Advisory 

Committee. 

General Function of the Committee: 

To provide advice and 

recommendations to the agency on 

FDA’s regulatory issues. 

Date and Time: The meeting will be 

held on February 20, 2008, from 8:30 

a.m. to approximately 4 p.m., and on 

February 21, 2008 from 8:30 a.m. to 

approximately 4:30 p.m. 

Location: Hilton Hotel DC North/ 

Gaithersburg, 620 Perry Pkwy., 

Gaithersburg, MD 20877. 

Contact Person: Christine Walsh or 

Denise Royster, Center for Biologics 

Evaluation and Research (HFM–71), 

Food and Drug Administration, 1401 

Rockville Pike, Rockville, MD 20852, 

301–827–0314, or FDA Advisory 

Committee Information Line, 1–800–

741–8138 (301–443–0572 in the 

Washington, DC area), code 

3014512391. Please call the Information 

Line for up-to-date information on this 

meeting. A notice in the Federal 

Register about last minute modifications 

that impact a previously announced 

advisory committee meeting cannot 

always be published quickly enough to 

provide timely notice. Therefore, you 

should always check the agency’s Web 

site and call the appropriate advisory 

committee hot line/phone line to learn 

about possible modifications before 

coming to the meeting. 

Agenda: On February 20, 2008, the 

committee will discuss and make 

recommendations on a rotavirus vaccine 

manufactured by GlaxoSmithKline 

Biologicals. On February 21, 2008, in 

the morning, the committee will discuss 

the selection of strains to be included in 

the influenza vaccine for the 2008—

2009 influenza season. In the afternoon, 

the committee will discuss clinical 

development of influenza vaccines for 

pandemic and pre-pandemic uses. 

FDA intends to make background 

material available to the public no later 

than 2 business days before the meeting. 

If FDA is unable to post the background 

material on its Web site prior to the 

meeting, the background material will 

be made publicly available at the 

location of the advisory committee 

meeting, and the background material 

will be posted on FDA’s Web site after 

the meeting. Background material is 

available at http://www.fda.gov/ohrms/ 

dockets/ac/acmenu.htm, click on the 

year 2008 and scroll down to the 

appropriate advisory committee link. 

Procedure: Interested persons may 

present data, information, or views, 

orally or in writing, on issues pending 

before the committee. Written 

submissions may be made to the contact 

person on or before February 13, 2008. 

Oral presentations from the public will 

be scheduled between approximately 1 

p.m. and 1:30 p.m. on February 20, 

2008, and approximately 11:20 a.m. and 

11:50 a.m. and 2:45 p.m. and 3:15 p.m. 

on February 21, 2008. Those desiring to 

make formal oral presentations should 

notify the contact person and submit a 

brief statement of the general nature of 

the evidence or arguments they wish to 

present, the names and addresses of 

proposed participants, and an 

indication of the approximate time 

requested to make their presentation on 

or before February 6, 2008. Time 

allotted for each presentation may be 

limited. If the number of registrants 

requesting to speak is greater than can 

be reasonably accommodated during the 

scheduled open public hearing session, 

FDA may conduct a lottery to determine 

the speakers for the scheduled open 

public hearing session. The contact 

person will notify interested persons 

regarding their request to speak by 

February 7, 2008. 

Persons attending FDA’s advisory 

committee meetings are advised that the 

agency is not responsible for providing 

access to electrical outlets. 

FDA welcomes the attendance of the 

public at its advisory committee 

meetings and will make every effort to 

accommodate persons with physical 

disabilities or special needs. If you 

require special accommodations due to 

a disability, please contact Christine 

Walsh or Denise Royster at least 7 days 

in advance of the meeting. 

FDA is committed to the orderly 

conduct of its advisory committee 

meetings. Please visit our Web site at 

http://www.fda.gov/oc/advisory/ 

default.htm for procedures on public 

conduct during advisory committee 

meetings. 

Notice of this meeting is given under 

the Federal Advisory Committee Act (5 

U.S.C. app. 2). 

Dated: January 24, 2008. 

Randall W. Lutter, 

Deputy Commissioner for Policy. 

[FR Doc. E8–1889 Filed 1–31–08; 8:45 am] 

BILLING CODE 4160–01–S 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Center for Scientific Review; Amended 

Notice of Meeting 

Notice is hereby given of a change in 

the meeting of the Center for Scientific 

Review Special Emphasis Panel, 

February 22, 2008, 8 a.m. to February 

22, 2008, 5 p.m., Holiday Inn 

Georgetown, 2101 Wisconsin Avenue, 

NW., Washington, DC 20007, which was 

published in the Federal Register on 

January 22, 2008, 73 FR 3733–3735. 

The meeting will be held February 21, 

2008, 6 p.m. to February 22, 2008, 7 

p.m. The meeting location remains the 

same. The meeting is closed to the 

public. 

Dated: January 25, 2008. 

Jennifer Spaeth, 

Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 08–435 Filed 1–31–08; 8:45 am] 

BILLING CODE 4140–01–M 

mstockstill on PROD1PC66 with NOTICES